Should EOAD patients be included in clinical trials?

Kinga Szigeti, Rachelle S Doody, Kinga Szigeti, Rachelle S Doody

Abstract

Alzheimer disease (AD) is a devastating neurodegenerative disease affecting 1 in 68 in the population. An arbitrary cutoff 65 years as the age of onset to distinguish between early- and late-onset AD has been proposed and has been used in the literature for decades. As the majority of patients develop AD after 65 years of age, most clinical trials address this population. While the early-onset cases represent only 1% to 6% of AD cases, this population is the active working subset and thus contributes to a higher public health burden per individual, and early-onset cases are the most devastating at the level of the individual and their families. In this review, we compare and contrast the clinical, neuropsychological, imaging, genetic, biomarker, and pathological features of these two arbitrary groups. Finally, we discuss the ethical dilemma of non-abandonment and justice as it pertains to exclusion of the early-onset AD patients from clinical trials.

References

    1. Amaducci LA, Rocca WA, Schoenberg BS. Origin of the distinction between Alzheimer's disease and senile dementia: how history can clarify nosology. Neurology. 1986;36:1497–1499.
    1. Campion D, Dumanchin C, Hannequin D, Dubois B, Belliard S, Puel M, Thomas-Anterion C, Michon A, Martin C, Charbonnier F, Raux G, Camuzat A, Penet C, Mesnage V, Martinez M, Clerget-Darpoux F, Brice A, Frebourg T. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet. 1999;65:664–670. doi: 10.1086/302553.
    1. Janssen JC, Beck JA, Campbell TA, Dickinson A, Fox NC, Harvey RJ, Houlden H, Rossor MN, Collinge J. Early onset familial Alzheimer's disease: mutation frequency in 31 families. Neurology. 2003;60:235–239.
    1. Signorini S, Ghidoni R, Barbiero L, Benussi L, Binetti G. Prevalence of pathogenic mutations in an Italian clinical series of patients with familial dementia. Curr Alzheimer Res. 2004;1:215–218. doi: 10.2174/1567205043332108.
    1. Dominantly Inherited Alzheimer Network homepage.
    1. Lleo A, Berezovska O, Growdon JH, Hyman BT. Clinical, pathological, and biochemical spectrum of Alzheimer disease associated with PS-1 mutations. Am J Geriatr Psychiatry. 2004;12:146–156.
    1. Joachim CL, Morris JH, Selkoe DJ. Clinically diagnosed Alzheimer's disease: autopsy results in 150 cases. Ann Neurol. 1988;24:50–56. doi: 10.1002/ana.410240110.
    1. Binetti G, Magni E, Padovani A, Cappa SF, Bianchetti A, Trabucchi M. Neuropsychological heterogeneity in mild Alzheimer's disease. Dementia. 1993;4:321–326.
    1. Licht EA, McMurtray AM, Saul RE, Mendez MF. Cognitive differences between early- and late-onset Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2007;22:218–222. doi: 10.1177/1533317506299156.
    1. Filley CM, Kelly J, Heaton RK. Neuropsychologic features of early- and late-onset Alzheimer's disease. Arch Neurol. 1986;43:574–576.
    1. Suribhatla S, Baillon S, Dennis M, Marudkar M, Muhammad S, Munro D, Spreadbury C, Lindesay J. Neuropsychological performance in early and late onset Alzheimer's disease: comparisons in a memory clinic population. Int J Geriatr Psychiatry. 2004;19:1140–1147. doi: 10.1002/gps.1196.
    1. Koedam EL, Lauffer V, van der Vlies AE, van der Flier WM, Scheltens P, Pijnenburg YA. Early-versus late-onset Alzheimer's disease: more than age alone. J Alzheimers Dis. 2010;19:1401–1408.
    1. Maurer K, Volk S, Gerbaldo H. Auguste D and Alzheimer's disease. Lancet. 1997;349:1546–1549. doi: 10.1016/S0140-6736(96)10203-8.
    1. Klünemann HH, Fronhöfer W, Wurster H, Fischer W, Ibach B, Klein HE. Alzheimer's second patient: Johann F. and his family. Ann Neurol. 2002;52:520–523. doi: 10.1002/ana.10309.
    1. Jacobs D, Sano M, Marder K, Bell K, Bylsma F, Lafleche G, Albert M, Brandt J, Stern Y. Age at onset of Alzheimer's disease: relation to pattern of cognitive dysfunction and rate of decline. Neurology. 1994;44:1215–1220.
    1. Koss E, Edland S, Fillenbaum G, Mohs R, Clark C, Galasko D, Morris JC. Clinical and neuropsychological differences between patients with earlier and later onset of Alzheimer's disease: a CERAD analysis, Part XII. Neurology. 1996;46:136–141.
    1. Rogaeva E. The solved and unsolved mysteries of the genetics of early-onset Alzheimer's disease. Neuromolecular Med. 2002;2:1–10. doi: 10.1385/NMM:2:1:01.
    1. Drachman DA, O'Donnell BF, Lew RA, Swearer JM. The prognosis in Alzheimer's disease. 'How far' rather than 'how fast' best predicts the course. Arch Neurol. 1990;47:851–856.
    1. Bracco L, Gallato R, Grigoletto F, Lippi A, Lepore V, Bino G, Lazzaro MP, Carella F, Piccolo T, Pozzilli C, Glometto B, Amaducci L. Factors affecting course and survival in Alzheimer's disease. A 9-year longitudinal study. Arch Neurol. 1994;51:1213–1219.
    1. Frisoni GB, Pievani M, Testa C, Sabattoli F, Bresciani L, Bonetti M, Beltramello A, Hayashi KM, Toga AW, Thompson PM. The topography of grey matter involvement in early and late onset Alzheimer's disease. Brain. 2007;130:720–730. doi: 10.1093/brain/awl377.
    1. Frisoni GB, Testa C, Sabattoli F, Beltramello A, Soininen H, Laakso MP. Structural correlates of early and late onset Alzheimer's disease: voxel based morphometric study. J Neurol Neurosurg Psychiatry. 2005;76:112–114. doi: 10.1136/jnnp.2003.029876.
    1. Shiino A, Watanabe T, Kitagawa T, Kotani E, Takahashi J, Morikawa S, Akiguchi I. Different atrophic patterns in early- and late-onset Alzheimer's disease and evaluation of clinical utility of a method of regional z-score analysis using voxel-based morphometry. Dement Geriatr Cogn Disord. 2008;26:175–186. doi: 10.1159/000151241.
    1. Karas G, Scheltens P, Rombouts S, van Schijndel R, Klein M, Jones B, van der Flier W, Vrenken H, Barkhof F. Precuneus atrophy in early-onset Alzheimer's disease: a morphometric structural MRI study. Neuroradiology. 2007;49:967–976. doi: 10.1007/s00234-007-0269-2.
    1. Salmon E, Collette F, Degueldre C, Lemaire C, Franck G. Voxel-based analysis of confounding effects of age and dementia severity on cerebral metabolism in Alzheimer's disease. Hum Brain Mapp. 2000;10:39–48. doi: 10.1002/(SICI)1097-0193(200005)10:1<39::AID-HBM50>;2-B.
    1. Sakamoto S, Ishii K, Sasaki M, Hosaka K, Mori T, Matsui M, Hirono N, Mori E. Differences in cerebral metabolic impairment between early and late onset types of Alzheimer's disease. J Neurol Sci. 2002;200:27–32. doi: 10.1016/S0022-510X(02)00114-4.
    1. Kim EJ, Cho SS, Jeong Y, Park KC, Kang SJ, Kang E, Kim SE, Lee KH, Na DL. Glucose metabolism in early onset versus late onset Alzheimer's disease: an SPM analysis of 120 patients. Brain. 2005;128:1790–1801. doi: 10.1093/brain/awh539.
    1. Rabinovici GD, Furst AJ, Alkalay A, Racine CA, O'Neil JP, Janabi M, Baker SL, Agarwal N, Bonasera SJ, Mormino EC, Weiner MW, Gorno-Tempini ML, Rosen HJ, Miller BL, Jagust WJ. Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden. Brain. 2010;133:512–528. doi: 10.1093/brain/awp326.
    1. Koivunen J, Verkkoniemi A, Aalto S, Paetau A, Ahonen JP, Viitanen M, Någren K, Rokka J, Haaparanta M, Kalimo H, Rinne JO. PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease. Brain. 2008;131:1845–1853. doi: 10.1093/brain/awn107.
    1. Villemagne VL, Ataka S, Mizuno T, Brooks WS, Wada Y, Kondo M, Jones G, Watanabe Y, Mulligan R, Nakagawa M, Miki T, Shimada H, O'Keefe GJ, Masters CL, Mori H, Rowe CC. High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch Neurol. 2009;66:1537–1544. doi: 10.1001/archneurol.2009.285.
    1. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol. 1999;56:673–680. doi: 10.1001/archneur.56.6.673.
    1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939–944.
    1. Nochlin D, van Belle G, Bird TD, Sumi SM. Comparison of the severity of neuropathologic changes in familial and sporadic Alzheimer's disease. Alzheimer Dis Assoc Disord. 1993;7:212–222.
    1. Bigio EH, Hynan LS, Sontag E, Satumtira S, White CL. Synapse loss is greater in presenile than senile onset Alzheimer disease: implications for the cognitive reserve hypothesis. Neuropathol Appl Neurobiol. 2002;28:218–227. doi: 10.1046/j.1365-2990.2002.00385.x.
    1. Marshall GA, Fairbanks LA, Tekin S, Vinters HV, Cummings JL. Early-onset Alzheimer's disease is associated with greater pathologic burden. J Geriatr Psychiatry Neurol. 2007;20:29–33. doi: 10.1177/0891988706297086.
    1. Jayadev S, Leverenz JB, Steinbart E, Stahl J, Klunk W, Yu CE, Bird TD. Alzheimer's disease phenotypes and genotypes associated with mutations in presenilin 2. Brain. 2010;133:1143–1154. doi: 10.1093/brain/awq033.
    1. Lippa CF, Schmidt ML, Nee LE, Bird T, Nochlin D, Hulette C, Mori H, Lee VM, Trojanowski JQ. AMY plaques in familial AD: comparison with sporadic Alzheimer's disease. Neurology. 2000;54:100–104.
    1. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C. et al.Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009;41:1088–1093. doi: 10.1038/ng.440.
    1. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fiévet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O. European Alzheimer's Disease Initiative Investigators. de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V. et al.Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009;41:1094–1099. doi: 10.1038/ng.439.
    1. Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, Bis JC, Smith AV, Carassquillo MM, Lambert JC, Harold D, Schrijvers EM, Ramirez-Lorca R, Debette S, Longstreth WT Jr, Janssens AC, Pankratz VS, Dartigues JF, Hollingworth P, Aspelund T, Hernandez I, Beiser A, Kuller LH, Koudstaal PJ, Dickson DW, Tzourio C, Abraham R, Antunez C, Du Y, Rotter JI. et al.Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010;303:1832–1840. doi: 10.1001/jama.2010.574.
    1. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921–923. doi: 10.1126/science.8346443.
    1. Elder GA, Gama Sosa MA, De Gasperi R. Transgenic mouse models of Alzheimer's disease. Mt Sinai J Med. 2010;77:69–81. doi: 10.1002/msj.20159.
    1. European Medicines Agency homepage.
    1. Council for International Organizations of Medical Sciences. International Ethical Guidelines for Biomedical Research Involving Human Subjects.
    1. US Food and Drug Administration homepage.
    1. Gericke C, Riesberg A, Busse R. Ethical issues in funding orphan drug research and development. J Med Ethics. 2005;31:164–168. doi: 10.1136/jme.2003.007138.
    1. Beauchamp TL, Childress JF. Principles of Biomedical Ethics. Oxford: Oxford University Press; 2001.
    1. Landmann W, Henley I. Equitable rationing of highly specialized health care services for children: a perspective from South Africa. J Med Ethics. 1999;25:224–229. doi: 10.1136/jme.25.3.224.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir